Veran Introduces SPiNPerc™, a New Procedure for Lung Specialists that Streamlines Patient Care by Allowing Access to Nodules Outside the Airways

CHICAGO, Oct. 29, 2013 /PRNewswire/ -- Veran announced its new SPiNPerc™ procedural innovation today at the American College of Chest Physician's Conference (CHEST 2013).  With recent announcements such as the U.S. Preventative Services Task Force's (USPSTF) recommendation for health insurance to cover lung cancer screening in high-risk patients, hospitals are actively organizing comprehensive lung cancer programs in preparation for the massive influx of patients requiring screening.

(Photo: http://photos.prnewswire.com/prnh/20131029/PH06700-a )
(Photo: http://photos.prnewswire.com/prnh/20131029/PH06700-b )

Today, patients face a complex and often frustrating process in lung cancer screening that involves multiple specialists, departments and visits.  With approximately 40% of lung lesions residing outside the airways, Veran allows lung physicians to quickly transition from a bronchoscopic to a percutaneous procedure to access these lesions.

Johns Hopkins in Baltimore, MD recently began enrolling patients into a clinical study on this innovative approach to caring for potential lung cancer patients. "We are excited to begin the first clinical study using SPiNPerc," Lonny Yarmus, D.O., Fellowship Director, Interventional Pulmonology and Assistant Professor of Medicine at Johns Hopkins said. "The ability to start with a bronchoscope and have the option to quickly change to a percutaneous procedure, if necessary, may provide lung doctors with a valuable tool for getting a diagnosis for our patients with suspicious peripheral lung nodules. I believe innovations like SPiNPerc, combined with effective education and screening programs, are an important part of our efforts to positively impact survival rates for lung cancer sufferers."

Rob Powers, Vice President of Marketing for Veran Medical Technologies, said, "SPiNPerc is providing lung specialists more tools than ever before to potentially get a diagnosis and begin treatment sooner.  When an endobronchial approach is not the best method to reach a nodule, the SPiNPerc procedure allows pulmonologists and thoracic surgeons to perform a percutaneous lung biopsy in the same setting. SPiNPerc is just another excellent example of how Veran's SPiNDrive navigation system is the most comprehensive ENB platform available."

Veran also launched several new products and programs at CHEST 2013, including the new SPiNView™ system, Veran's Yield Optimization Program, SPiNFlex and a comprehensive patient & physician education program. 

About Veran Medical Technologies. Veran Medical Technologies is a privately held soft tissue navigation company focused on the early diagnosis of cancer.  Multiple specialties use Veran's electromagnetic navigation platform to enhance hospital oncology programs.  The technology is used to assist with lung, kidney and liver procedures endobronchially or percutaneously for biopsies, ablations, drainages and more.   Veran Medical Technologies is headquartered in St. Louis, MO.

Veran Medical Technologies Media Contact

Michelle Berkley, Marketing Manager | 314.659.8500 | www.veranmedical.com

Read more news from Veran Medical Technologies.

SOURCE Veran Medical Technologies